Janux Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Research and development | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| Balance Sheet | |||||
| Cash and equivalents | $52.3M | $430.6M | $19.2M | $51.4M | $35.6M |
| Current assets | $975.9M | $1.0B | $349.2M | $332.4M | $377.0M |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M |
| Current liabilities | $25.0M | $17.5M | $13.0M | $16.5M | $12.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Stockholders' equity | $956.8M | $1.0B | $344.3M | $320.7M | $366.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Depreciation and amortization | $2.0M | $2.1M | $2.0M | $841,000 | $113,000 |
| Stock-based compensation | $40.2M | $33.0M | $20.0M | $17.2M | $6.9M |
| Capital expenditure | $1.0M | $359,000 | $1.9M | $6.4M | $1.5M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 61.0M · Free float 41.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.